Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label brivaracetam study in childhood or juvenile absence epilepsy
2020-002769-33Phase 3Terminated
- Sponsor
- UCB
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of brivaracetam in childhood absence epilepsy (CAE) and juvenile absence epilepsy (JAE), sponsored by UCB. Primary endpoint: Percentage of participants with treatment-emergent adverse events. Started Dec 2020; status: terminated.
02
Drugs
brivaracetam
03
Conditions
childhood absence epilepsy (CAE)juvenile absence epilepsy (JAE)
Beyond the preview
Go deeper on 2020-002769-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002769-33.